Effect of aspirin on the outcomes in adult patients with ischemic moyamoya disease treated with encephaloduroarteriosynangiosis
10.3760/cma.j.issn.1673-4165.2022.02.005
- VernacularTitle:阿司匹林对接受脑-硬膜-动脉融通术治疗的成年缺血型烟雾病患者转归的影响
- Author:
Rimiao YANG
1
;
Bo ZHAO
;
Fangbin HAO
;
Qian ZHANG
;
Xiangyang BAO
;
Zhengshan ZHANG
;
Cong HAN
;
Lian DUAN
Author Information
1. 解放军总医院第五医学中心神经外科，北京 100039
- Keywords:
Moyamoya disease;
Brain ischemia;
Cerebral revascularization;
Aspirin;
Treatment outcome
- From:
International Journal of Cerebrovascular Diseases
2022;30(2):104-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of aspirin on the outcomes in adult patients with ischemic moyamoya disease treated with encephaloduroarteriosynangiosis (EDAS).Methods:Adult patients with ischemic moyamoya disease treated EDAS in the Department of Neurosurgery, the Fifth Medical Center, PLA General Hospital from January 2015 to September 2018 were enrolled retrospectively. The control group only received EDAS treatment, and the aspirin group received EDAS and aspirin antiplatelet treatment. The data of the both groups were analyzed retrospectively and the effective rate of operation, the incidence of perioperative intracerebral hemorrhage, the incidence of recurrent cerebrovascular events at 6 months after operation and the improvement rate of the modified Rankin Scale (mRS) score were compared.Results:A total of 120 adult patients with ischemic moyamoya disease were enrolled, including 60 in the aspirin group and 60 in the control group. EDAS was performed on 107 cerebral hemispheres in both groups. The operative effective rate in the aspirin group was significantly higher than that in the control group (82.24% vs. 65.42%; χ2=7.836, P=0.005). There was no perioperative cerebral hemorrhage event in the aspirin group and the control group. There was no significant difference in the incidence of cerebral infarction within 6 months after operation, but the incidence of transient ischemic attack in the aspirin group was significantly lower than that in the control group (15% vs. 40%; χ2=9.404, P=0.002). In addition, the improvement rate of mRS score in the aspirin group at 6 months after operation was significantly higher than that in the control group (85% vs. 63.33%; χ2=7.350, P=0.007). Conclusions:The combination of EDAS and aspirin can effectively improve the outcomes of adult patients with ischemic moyamoya disease without increasing the risk of perioperative intracerebral hemorrhage.
